Literature DB >> 16053901

Germ-line and somatic PTPN11 mutations in human disease.

Marco Tartaglia1, Bruce D Gelb.   

Abstract

Reversible protein tyrosyl phosphorylation of cell surface receptors and downstream intracellular transducers is a major regulatory mechanism used to modulate cellular responses to extracellular stimuli, and its deregulation frequently drives aberrant cell proliferation, survival and/or differentiation. SHP-2 is a cytoplasmic Src-homology 2 domain-containing protein tyrosine phosphatase that plays an important role in intracellular signaling and is required during development and hematopoiesis. Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related developmental disorders. More recently, a distinct class of missense mutations in the same gene has been identified to occur as a somatic event contributing to myeloid and lymphoid malignancies. This review focuses on the role of SHP-2 in signal transduction, development and hematopoiesis, as well as on the consequences of SHP-2 gain-of-function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16053901     DOI: 10.1016/j.ejmg.2005.03.001

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  46 in total

Review 1.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

2.  Potentiation of Helicobacter pylori CagA protein virulence through homodimerization.

Authors:  Lisa Nagase; Naoko Murata-Kamiya; Masanori Hatakeyama
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

3.  Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.

Authors:  Anna Papadopoulou; Michalis Issakidis; Evangelia Gole; Konstantina Kosma; Helen Fryssira; Andreas Fretzayas; Polyxeni Nicolaidou; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2011-05-18       Impact factor: 3.183

4.  Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.

Authors:  Emilie A Bard-Chapeau; Shuangwei Li; Jin Ding; Sharon S Zhang; Helen H Zhu; Frederic Princen; Diane D Fang; Tao Han; Beatrice Bailly-Maitre; Valeria Poli; Nissi M Varki; Hongyang Wang; Gen-Sheng Feng
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

Review 5.  Signalling by protein phosphatases and drug development: a systems-centred view.

Authors:  Lan K Nguyen; David Matallanas; David R Croucher; Alexander von Kriegsheim; Boris N Kholodenko
Journal:  FEBS J       Date:  2012-03-14       Impact factor: 5.542

6.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Authors:  Rebecca J Chan; Gen-Sheng Feng
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

7.  Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

Authors:  Suman Kundu; Keke Fan; Mingli Cao; Daniel J Lindner; Zhizhaung Joe Zhao; Ernest Borden; Taolin Yi
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

Review 8.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

9.  Identification of cancer-associated gene clusters and genes via clustering penalization.

Authors:  Shuangge Ma; Jian Huang; Shihao Shen
Journal:  Stat Interface       Date:  2009-01-01       Impact factor: 0.582

10.  Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome.

Authors:  John M Graham; Nancy Kramer; Bassem A Bejjani; Christian T Thiel; Claudio Carta; Giovanni Neri; Marco Tartaglia; Martin Zenker
Journal:  Am J Med Genet A       Date:  2009-10       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.